Natixis’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Natixis’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78M	Buy	492,616 +3,812	+0.8%	+$515K	0.31%	46
2026 Q1	$62.4M	Sell	488,804 -4,245	-0.9%	-$530K	0.22%	59
2025 Q4	$60.1M	Sell	493,049 -4,847	-1%	-$556K	0.21%	61
2025 Q3	$49.9M	Sell	497,896 -2,104	-0.4%	-$190K	0.23%	69
2025 Q2	$41.5M	Hold	500,000	–	–	0.18%	80
2025 Q1	$40.3M	Buy	+500,000	New	+$44.7M	0.22%	71
2023 Q1	–	Sell	-3	Closed	-$249	–	1229
2022 Q4	$249	Buy	+3	New	+$243	﹤0.01%	1053
2020 Q4	–	Sell	-1,000,000	Closed	-$111M	–	1111
2020 Q3	$111M	Buy	+1,000,000	New	+$112M	0.82%	29
2020 Q2	–	Sell	-2,000,000	Closed	-$155M	–	869
2020 Q1	$155M	Hold	2,000,000	–	–	1.22%	12
2019 Q4	$190M	Buy	2,000,000 +1,960,460	+4,958%	+$170M	1.18%	7
2019 Q3	$3.02M	Buy	39,540 +8,929	+29%	+$742K	0.02%	433
2019 Q2	$2.69M	Sell	30,611 -1,229	-4%	-$105K	0.02%	409
2019 Q1	$2.83M	Sell	31,840 -39,015	-55%	-$3.32M	0.02%	458
2018 Q4	$5.08M	Buy	70,855 +30,561	+76%	+$2.46M	0.04%	319
2018 Q3	$3.86M	Sell	40,294 -9,204	-19%	-$892K	0.02%	412
2018 Q2	$4.71M	Buy	49,498 +2,594	+6%	+$238K	0.02%	389
2018 Q1	$4.12M	Buy	46,904 +14,806	+46%	+$1.35M	0.03%	395
2017 Q4	$2.72M	Buy	32,098 +9,250	+40%	+$775K	0.02%	373
2017 Q3	$1.98M	Sell	22,848 -327,152	-93%	-$26.2M	0.02%	417
2017 Q2	$27M	Buy	350,000 +225,028	+180%	+$16M	0.31%	84
2017 Q1	$8.65M	Buy	124,972 +41,667	+50%	+$2.8M	0.11%	183
2016 Q4	$4.93M	Buy	83,305 +23,656	+40%	+$1.46M	0.05%	263
2016 Q3	$3.95M	Buy	+59,649	New	+$3.69M	0.05%	217
2015 Q4	–	Sell	-8,364	Closed	-$521K	–	374
2015 Q3	$521K	Buy	8,364 +2,424	+41%	+$191K	0.01%	193
2015 Q2	$499K	Buy	+5,940	New	+$462K	0.01%	257

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Natixis's XBI Position: Q2 2026 in Review

Natixis increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.78% in Q2 2026, buying an estimated $515K and bringing the position to 492,616 shares worth $78M. The position accounts for 0.31% of the portfolio, ranked #46.

Natixis first reported a position in XBI in Q2 2015 and has held it in 25 quarters since. The position peaked at $190M in Q4 2019. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Natixis held 492,616 shares of State Street SPDR S&P Biotech ETF worth $78M as of Q2 2026.
Natixis bought 3,812 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $515K.
State Street SPDR S&P Biotech ETF made up 0.31% of Natixis's portfolio in Q2 2026, its #46 holding.
Natixis first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and has held it in 25 quarters since.
Natixis's State Street SPDR S&P Biotech ETF position peaked at $190M in Q4 2019.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.